BioAlliance Pharma announces new opportunities for its Patented Lauriad™ mucoadhesive technology

New collaborative programs

Paris, December 15, 2010 – BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

A first funding from the ANR is allocated to the development of a Lauriad™ mucoadhesive tablet containing a siRNA (small interfering RNA targeting the androgen receptors) intended for the treatment of castration-resistant prostate cancer. This program is managed in partnership with SeleXel, the company developing this biological molecule. This proof of concept should be extended to other similar molecules.

Medicen Paris Region and Atlanpole have also just granted another label to "Fluriad", another program involving several academic centers (Paris XI and Lyon 1 Universities, Nice University Hospital) and industrial partners (Sogeval, a veterinary drug company and Gredeco, developing mucous penetration models).The consortium, led by BioAlliance, is at designing vaccines administered by mucosal route, using the innovative properties of the mucoadhesive Lauriad™ technology. These label awards from "Clusters of excellence" are a first step toward new opportunities for public grants, allocated to small and mid-sized companies.

"These new collaborations involving our Lauriad™ mucoadhesive delivery system are essentially based on the achievements and clinical experience from our two first innovative products (Loramyc®, registered in Europe and in the United-States, and Sitavir™, registration dossier to be filed). This new mucosal route has been validated by the European and US Agencies and opens new opportunities for the mucosal administration of complex biological products", stated Dominique Costantini, Chief Executive Officer of BioAlliance Pharma.

About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries, in Korea and in the United States
Setofilm® (prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Sitavir™ (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results
AMEP® (invasive melanoma): Phase I
Clonidine Lauriad™ (mucositis): Phase II
Doxorubicin Transdrug® (liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com